Depletion of CD206+ Tumour Macrophages via a Peptide-Targeted Star-Shaped Polyglutamate Inhibits Tumourigenesis and Metastatic Dissemination in Mouse Breast Cancer Models

Although many studies have explored the depletion of tumour-associated macrophages (TAMs) as a therapeutic strategy for solid tumours, currently available compounds suffer from poor efficacy and dose-limiting side effects. Here, we developed a novel TAM-depleting agent ("OximUNO") that specifically targets CD206+ TAMs and demonstrated efficacy in triple negative breast cancer (TNBC) mouse models. OximUNO comprises a star-shaped polyglutamate (St-PGA) decorated with the CD206-targeting peptide mUNO that carries the chemotherapeutic drug doxorubicin (DOX). In TNBC models, a fluorescently-labelled mUNO-decorated St-PGA homed to CD206+ TAMs within primary lesions and metastases. OximUNO exhibited no acute liver or kidney toxicity in vivo. Treatment with OximUNO reduced the progression of primary tumour lesions and pulmonary metastases, significantly diminished the number of CD206+ TAMs and increased the CD8/FOXP3 expression ratio (demonstrating immunostimulation). Our findings suggest the potential benefit of OximUNO as a TAM-depleting agent for TNBC treatment. Importantly, our studies also represent the first report of a peptide-targeted St-PGA as a targeted therapeutic nanoconjugate.

Download Full-text

Depletion of CD206+ Tumour Macrophages via a Peptide Targeted Star-Shaped Polyglutamate Inhibits Tumourigenesis and Metastatic Dissemination in Mouse Breast Cancer Models

10.21203/rs.3.rs-839856/v2 ◽

2021 ◽

Author(s):

Anni Lepland ◽

Alessio Malfanti ◽

Uku Haljasorg ◽

Eliana Asciutto ◽

Monica Pickholz ◽

...

Keyword(s):

Breast Cancer ◽

Therapeutic Strategy ◽

Primary Tumour ◽

Foxp3 Expression ◽

Expression Ratio ◽

Cancer Models ◽

Mouse Breast Cancer ◽

Targeting Peptide ◽

Poor Efficacy

Abstract Although many studies have explored the depletion of tumour-associated macrophages (TAMs) as a therapeutic strategy for solid tumours, currently available compounds suffer from poor efficacy and dose-limiting side effects. Here, we developed a novel TAM-depleting agent ("OximUNO") that specifically targets CD206+ TAMs and demonstrated efficacy in triple negative breast cancer (TNBC) mouse models. OximUNO comprises a star-shaped polyglutamate (St-PGA) decorated with the CD206-targeting peptide mUNO that carries the chemotherapeutic drug doxorubicin (DOX). In TNBC models, a fluorescently-labelled mUNO-decorated St-PGA homed to CD206+ TAMs within primary lesions and metastases. OximUNO exhibited no acute liver or kidney toxicity in vivo. Treatment with OximUNO reduced the progression of primary tumour lesions and pulmonary metastases, significantly diminished the number of CD206+ TAMs and increased the CD8/FOXP3 expression ratio (demonstrating immunostimulation). Our findings suggest the potential benefit of OximUNO as a TAM-depleting agent for TNBC treatment. Importantly, our studies also represent the first report of a peptide-targeted St-PGA as a targeted therapeutic nanoconjugate.

Download Full-text

The truncated somatostatin receptor sst5TMD4 stimulates the production of pro-angiogenic factors in in vitro and in vivo breast cancer models

Endocrine Abstracts ◽

10.1530/endoabs.35.p516 ◽

2014 ◽

Author(s):

Raul M Luque ◽

Mario Duran-Prado ◽

David Rincon-Fernandez ◽

Marta Hergueta-Redondo ◽

Michael D Culler ◽

...

Keyword(s):

Breast Cancer ◽

Somatostatin Receptor ◽

Angiogenic Factors ◽

Cancer Models

Download Full-text

Controllable Drug Delivery by Na+/K+ ATPase α1 Targeting Peptide Conjugated DSPE-PEG Nanocarriers for Breast Cancer

Technology in Cancer Research & Treatment ◽

10.1177/15330338211027898 ◽

2021 ◽

Vol 20 ◽

pp. 153303382110278

Author(s):

Yayan Yang ◽

Qian Feng ◽

Chuanfeng Ding ◽

Wei Kang ◽

Xiufeng Xiao ◽

...

Keyword(s):

Breast Cancer ◽

Drug Delivery ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Click Reaction ◽

Chemotherapy Drugs ◽

Targeting Peptide ◽

And Migration

Although Epirubicin (EPI) is a commonly used anthracycline for the treatment of breast cancer in clinic, the serious side effects limit its long-term administration including myelosuppression and cardiomyopathy. Nanomedicines have been widely utilized as drug delivery vehicles to achieve precise targeting of breast cancer cells. Herein, we prepared a DSPE-PEG nanocarrier conjugated a peptide, which targeted the breast cancer overexpression protein Na+/K+ ATPase α1 (NKA-α1). The nanocarrier encapsulated the EPI and grafted with the NKA-α1 targeting peptide through the click reaction between maleimide and thiol groups. The EPI was slowly released from the nanocarrier after entering the breast cancer cells with the guidance of the targeting NKA-α1 peptide. The precise and controllable delivery and release of the EPI into the breast cancer cells dramatically inhibited the cells proliferation and migration in vitro and suppressed the tumor volume in vivo. These results demonstrate significant prospects for this nanocarrier as a promising platform for numerous chemotherapy drugs.

Download Full-text

Abstract LB168: Blocking SIRPα on myeloid cells synergizes with radiation therapy in mouse breast cancer models

10.1158/1538-7445.am2021-lb168 ◽

2021 ◽

Author(s):

Claire Lhuillier ◽

Maud Charpentier ◽

Sergio Trombetta ◽

Sandra Demaria

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Myeloid Cells ◽

Cancer Models ◽

Mouse Breast Cancer

Download Full-text

PP 46 In vivo imaging of modulation of IGF-1R expression in breast cancer models

European Journal of Cancer ◽

10.1016/s0959-8049(11)72659-4 ◽

2011 ◽

Vol 47 ◽

pp. S19 ◽

Cited By ~ 1

Author(s):

S. Heskamp ◽

O.C. Boerman ◽

W.J.G. Oyen ◽

J.D.M. Molkenboer-Kuenen ◽

W.T.A. van der Graaf ◽

...

Keyword(s):

Breast Cancer ◽

In Vivo Imaging ◽

Cancer Models

Download Full-text

Nanostructured Dihydroartemisinin Plus Epirubicin Liposomes Enhance Treatment Efficacy of Breast Cancer by Inducing Autophagy and Apoptosis

Nanomaterials ◽

10.3390/nano8100804 ◽

2018 ◽

Vol 8 (10) ◽

pp. 804 ◽

Cited By ~ 3

Author(s):

Ying-Jie Hu ◽

Jing-Ying Zhang ◽

Qian Luo ◽

Jia-Rui Xu ◽

Yan Yan ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Therapeutic Strategy ◽

Beclin 1 ◽

Type I ◽

Programmed Death ◽

Cancer Tissues

The heterogeneity of breast cancer and the development of drug resistance are the relapse reasons of disease after chemotherapy. To address this issue, a combined therapeutic strategy was developed by building the nanostructured dihydroartemisinin plus epirubicin liposomes. Investigations were performed on human breast cancer cells in vitro and xenografts in nude mice. The results indicated that dihydroartemisinin could significantly enhance the efficacy of epirubicin in killing different breast cancer cells in vitro and in vivo. We found that the combined use of dihydroartemisinin with epirubicin could efficiently inhibit the activity of Bcl-2, facilitate release of Beclin 1, and further activate Bax. Besides, Bax activated apoptosis which led to the type I programmed death of breast cancer cells while Beclin 1 initiated the excessive autophagy that resulted in the type II programmed death of breast cancer cells. In addition, the nanostructured dihydroartemisinin plus epirubicin liposomes prolonged circulation of drugs, and were beneficial for simultaneously delivering drugs into breast cancer tissues. Hence, the nanostructured dihydroartemisinin plus epirubicin liposomes could provide a new therapeutic strategy for treatment of breast cancer.

Download Full-text